UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
Phase 2
Completed
- Conditions
- Neuralgia, Postherpetic
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT00160511
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
Phase 3
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Certolizumab Pegol (CDP870)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 310
- Registration Number
- NCT00160706
- Locations
- 🇺🇸
45141, Seattle, Washington, United States
🇺🇸45022, Houston, Texas, United States
🇿🇦39004, PORT Elisabeth, South Africa
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 729
- Registration Number
- NCT00160589
POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)
Phase 4
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 200
- Registration Number
- NCT00160537
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 251
- Registration Number
- NCT00160654
- Locations
- 🇸🇬
N01036 806, Singapore, Singapore
🇨🇳N01036 818, Tainan, Taiwan
🇲🇾N01036 813, Kuala Lumpur, Malaysia
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 207
- Registration Number
- NCT00160563
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 152
- Registration Number
- NCT00160667
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
Not Applicable
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-03-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 180
- Registration Number
- NCT00160498
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
Phase 3
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Certolizumab Pegol (CDP870)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 596
- Registration Number
- NCT00160524
- Locations
- 🇨🇿
18009, Melnik, Czechia
🇵🇱33009, Warszawa, Poland
🇷🇸35005, Belgrade, Serbia
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Certolizumab Pegol
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 402
- Registration Number
- NCT00160693
© Copyright 2025. All Rights Reserved by MedPath